2022年度ADC在胰腺癌领域的研究新进展及展望

曾铖; 张剑

doi:10.19401/j.cnki.1007-3639.2023.03.006

您当前的位置：

首页 >

文章列表页 >

2022年度ADC在胰腺癌领域的研究新进展及展望

专家述评 | 更新时间：2025-12-31

- 2022年度ADC在胰腺癌领域的研究新进展及展望
- Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022
- 中国癌症杂志 2023年33卷第3期页码：235-240
- 作者机构：
  
  复旦大学附属肿瘤医院Ⅰ期临床试验病房，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
  
  [ "曾铖（ORCID: 0009-0005-5307-3822），硕士在读。" ]
  [ "张剑，复旦大学附属肿瘤医院Ⅰ期临床试验病房行政主任，肿瘤内科主任医师、教授、硕士研究生导师。现任上海市抗癌协会肿瘤药物临床研究专业委员会候任主任委员，长江学术带乳腺联盟主任委员，中国抗癌协会乳腺癌专业委员会常委，中国抗癌协会乳腺癌专业委员会青年委员会副召集人，中国研究型医院协会乳腺专业委员会副主任委员，国家抗肿瘤药物临床应用监测青年委员会副主任委员，乳腺癌整合防治全国专家委员会青年委员会副主任委员，上海市抗癌协会肿瘤药学专业委员会副主任委员，中国临床肿瘤学会肿瘤支持与康复治疗专家委员会常委，中国康复医学会肿瘤康复专业委员会常委，中国临床肿瘤学会青年专家委员会常委，中国临床肿瘤学会乳腺癌专家委员会委员，中国抗癌协会肿瘤临床研究管理学专业委员会委员，国家药品监督管理局药品审评中心首批化药临床兼职审评员。Disease & Research 副主编。以第一作者、共同第一作者和通信作者在SCI收录期刊上发表论文40余篇。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.03.006
  中图分类号： R735.9
- 收稿：2023-01-30，
  
  修回：2023-02-23，
  
  纸质出版：2023-03-30
- 稿件说明：
移动端阅览
曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023,33(3):235-240.

Cheng ZENG, Jian ZHANG. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022[J]. China Oncology, 2023, 33(3): 235-240.
曾铖, 张剑. 2022年度ADC在胰腺癌领域的研究新进展及展望[J]. 中国癌症杂志, 2023,33(3):235-240. DOI： 10.19401/j.cnki.1007-3639.2023.03.006.

Cheng ZENG, Jian ZHANG. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022[J]. China Oncology, 2023, 33(3): 235-240. DOI： 10.19401/j.cnki.1007-3639.2023.03.006.

摘要

胰腺癌是发病率高且生存率低的一种恶性肿瘤，对于缺乏手术适应证及放化疗效果不好的患者，急需发展新型而高效的治疗手段。近年来，抗体药物偶联物（antibody-drug conjugate，ADC）因其高选择性和抗肿瘤活性等优点而逐渐成为研究热点，在胰腺癌的治疗中已取得一些成果，但是仍需面对诸多挑战。本文对2022年度ADC在胰腺癌领域的研究新进展进行综述。

Abstract

Pancreatic cancer is a type of malignant tumor with high incidence and low survival rate. It is urgent to develop novel and efficient therapeutic means for patients lacking surgical indications and patients with poor effects of radiotherapy and chemotherapy. In recent years

antibody-drug conjugate (ADC) has become hot because of their high selectivity and anti-tumor activity. ADC has achieved some results in the treatment of pancreatic cancer

but still face many challenges. This article provided a brief review of the latest developments of ADC in pancreatic cancer in 2022.

关键词

Keywords

references

CABASAG C J , FERLAY J , LAVERSANNE M , et al . Pancreatic cancer: an increasing global public health concern [J ] . Gut , 2022 , 71 ( 8 ): 1686 - 1687 .

HOSEIN A N , BREKKEN R A , MAITRA A . Pancreatic cancer stroma: an update on therapeutic targeting strategies [J ] . Nat Rev Gastroenterol Hepatol , 2020 , 17 ( 8 ): 487 - 505 . DOI: 10.1038/s41575-020-0300-1 http://doi.org/10.1038/s41575-020-0300-1

CHAU C H , STEEG P S , FIGG W D . Antibody-drug conjugates for cancer [J ] . Lancet , 2019 , 394 ( 10200 ): 793 - 804 . DOI: S0140-6736(19)31774-X http://doi.org/S0140-6736(19)31774-X

QI C S , GONG J F , LI J , et al . Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results [J ] . Nat Med , 2022 , 28 ( 6 ): 1189 - 1198 . DOI: 10.1038/s41591-022-01800-8 http://doi.org/10.1038/s41591-022-01800-8

KYUNO D , TAKASAWA A , TAKASAWA K , et al . Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials [J ] . Tissue Barriers , 2022 , 10 ( 1 ): 196 7080.

XU R H , WEI X L , ZHANG D S , et al . A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors [J ] . J Clin Oncol , 2023 , 41 ( 4_suppl ): 352 .

CAZES A , BETANCOURT O , ESPARZA E , et al . A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer [J ] . Clin Cancer Res , 2021 , 27 ( 7 ): 2100 - 2110 . DOI: 10.1158/1078-0432.CCR-20-3210 http://doi.org/10.1158/1078-0432.CCR-20-3210

JIN Y B , ZHANG Z H , ZOU S Y , et al . A novel c-MET-targeting antibody-drug conjugate for pancreatic cancer [J ] . Front Oncol , 2021 , 11 : 634881.

GYMNOPOULOS M , BETANCOURT O , BLOT V , et al . TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors [J ] . Mol Oncol , 2020 , 14 ( 1 ): 54 - 68 . DOI: 10.1002/1878-0261.12600 http://doi.org/10.1002/1878-0261.12600

NAKANO T . Systemic treatment of malignant pleural mesothelioma [J ] . Gan To Kagaku Ryoho , 2017 , 44 ( 13 ): 2041 - 2047 .

HASSAN R , BLUMENSCHEIN G R Jr , MOORE K N , et al . First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 16 ): 1824 - 1835 . DOI: 10.1200/JCO.19.02085 http://doi.org/10.1200/JCO.19.02085

SPILIOPOULOU P , KASI A , ABUSHAHIN L I , et al . Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208 [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 4136 . DOI: 10.1200/JCO.2022.40.16_suppl.4136 http://doi.org/10.1200/JCO.2022.40.16_suppl.4136 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4136 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4136

CUBAS R , ZHANG S , LI M , et al . Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway [J ] . Mol Cancer , 2010 , 9 : 253 . DOI: 10.1186/1476-4598-9-253 http://doi.org/10.1186/1476-4598-9-253

CARDILLO T M , GOVINDAN S V , SHARKEY R M , et al . Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers [J ] . Bioconjug Chem , 2015 , 26 ( 5 ): 919 - 931 . DOI: 10.1021/acs.bioconjchem.5b00223 http://doi.org/10.1021/acs.bioconjchem.5b00223 https://pubs.acs.org/doi/10.1021/acs.bioconjchem.5b00223 https://pubs.acs.org/doi/10.1021/acs.bioconjchem.5b00223

BARDIA A , MESSERSMITH W A , KIO E A , et al . Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial [J ] . Ann Oncol , 2021 , 32 ( 6 ): 746 - 756 . DOI: 10.1016/j.annonc.2021.03.005 http://doi.org/10.1016/j.annonc.2021.03.005 https://linkinghub.elsevier.com/retrieve/pii/S0923753421008838 https://linkinghub.elsevier.com/retrieve/pii/S0923753421008838

YANG M C , SHIA C S , LI W F , et al . Preclinical studies of OBI-999: a novel globo H-targeting antibody-drug conjugate [J ] . Mol Cancer Ther , 2021 , 20 ( 6 ): 1121 - 1132 . DOI: 10.1158/1535-7163.MCT-20-0763 http://doi.org/10.1158/1535-7163.MCT-20-0763 https://aacrjournals.org/mct/article/20/6/1121/673274/Preclinical-Studies-of-OBI-999-A-Novel-Globo-H https://aacrjournals.org/mct/article/20/6/1121/673274/Preclinical-Studies-of-OBI-999-A-Novel-Globo-H

HAN Z W , LYV Z W , CUI B , et al . The old CEACAMs find their new role in tumor immunotherapy [J ] . Invest New Drugs , 2020 , 38 ( 6 ): 1888 - 1898 . DOI: 10.1007/s10637-020-00955-w http://doi.org/10.1007/s10637-020-00955-w

DERY K J , GAUR S , GENCHEVA M , et al . Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M [J ] . J Biol Chem , 2011 , 286 ( 18 ): 16039 - 16051 . DOI: 10.1074/jbc.M110.204057 http://doi.org/10.1074/jbc.M110.204057

TIAN B M , WONG W Y , UGER M D , et al . Development and characterization of a camelid single domain antibody-urease conjugate that targets vascular endothelial growth factor receptor 2 [J ] . Front Immunol , 2017 , 8 : 956 . DOI: 10.3389/fimmu.2017.00956 http://doi.org/10.3389/fimmu.2017.00956

TIAN B , WONG W Y , HEGMANN E , et al . Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer [J ] . Bioconjugate Chem , 2015 , 26 ( 6 ): 1144 - 1155 . DOI: 10.1021/acs.bioconjchem.5b00237 http://doi.org/10.1021/acs.bioconjchem.5b00237

SINGH C S B , EYFORD B A , ABRAHAM T , et al . Discovery of a highly conserved peptide in the iron transporter melanotransferrin that traverses an intact blood brain barrier and localizes in neural cells [J ] . Front Neurosci , 2021 , 15 : 596976.

浏览量

3819

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2024年胰腺癌研究及诊疗新进展

2023年度胰腺癌研究及诊疗新进展

2022年度胰腺癌研究及诊疗新进展

2021年胰腺癌研究及诊疗新进展

2020年胰腺癌研究及诊疗新进展